1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > European Physicians’ Biosimilar Views: A Primer

European Physicians’ Biosimilar Views: A Primer

  • March 2014
  • -
  • Industry Standard Research
  • -
  • 40 pages

In February 2014, Alvogen announced the launch of Inflectra (infliximab) into Central and Eastern Europe. Inflectra is a biosimilar medicine to the reference medicinal product, Remicade, and is the first monoclonal antibody to be approved through the European Medicines Agency (EMA) biosimilars regulatory pathway. Remicade recorded European sales of over USD 2 billion in 2012.

So the biosimilar approvals are coming, but will physicians prescribe them? To find out, ISR asked 348 board-certified physicians across Spain, Italy, France, and Germany what they thought about prescribing biosimilar products.

What you will learn in this report:

- European physicians’ familiarity with biologic and biosimilar medicines
- Physician attitudes toward clinical development requirements for biosimilar medicines
- Physician views on pharmacy-level substitutions
- Importance of medication cost when prescribing
- Impact biosimilar pricing has on prescribing recommendations
- Physician concern with safety and efficacy of biosimilar products
- Current and future prescribing behavior for biosimilar medicines

Methodologies:
348 European physicians were surveyed for this report on the biosimilar landscape in France (N=87), Spain (N=87), Germany (N=87), and Italy (N=87).

To qualify to take this survey, physicians had to pass several screening criteria:

- Had to currently prescribe medications to patients
- Had to be board certified in one of the following therapeutic areas:

- Dermatology
- Endocrinology
- Gastrointestinal
- Hematology oncology
- Nephrology
- Neurology
- Oncology
- Rheumatology

Table Of Contents

European Physicians’ Biosimilar Views: A Primer
Table of Contents

Copyright and Usage Guidelines 3
Introduction 4
Methodology 5
Analysis note 6
Definition of biosimilars 7
Demographics and Qualifications 8
Practice environment description 8
Tenure in healthcare 10
Practice area/ specialty 11
Weekly patient volume 13
Biologic prescribing 14
Executive Summary 15
Familiarity 23
Biologic medicines 24
Biosimilar medicines 25
Regulatory 26
Clinical development requirements 27
Pharmacy-level substitution - agree/disagree 28
Past, present, and future influence of government payers in prescribing options 29
Economics 30
Importance of medication cost on prescribing 31
Biosimilar pricing and the impact on prescribing recommendations 32
Biosimilar prescribing behavior 33
Bigger biosimilar concern - safety or efficacy 34
Likelihood to prescribe a biosimilar 35
Ability to prescribe an original product when a biosimilar exists 36
Current level of flexibility in prescribing biologic/ biosimilar products 37
Future level of flexibility in prescribing biologic/ biosimilar products 38
Impact of prescribing based on manufacturer 39
About Industry Standard Research 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.